
## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9302952/publications.pdf Version: 2024-02-01



**FROUNTIC** 

#	Article	IF	CITATIONS
1	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
2	Visual dysfunction in Parkinson disease without dementia. Neurology, 2005, 65, 1907-1913.	1.5	268
3	Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology, 2014, 83, 413-425.	1.5	180
4	Predictors of driving safety in early Alzheimer disease. Neurology, 2009, 72, 521-527.	1.5	170
5	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Movement Disorders, 2010, 25, 2501-2507.	2.2	155
6	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Reviews in the Neurosciences, 2013, 24, 267-78.	1.4	152
7	Impaired visual search in drivers with Parkinson's disease. Annals of Neurology, 2006, 60, 407-413.	2.8	143
8	Driver route-following and safety errors in early Alzheimer disease. Neurology, 2004, 63, 832-837.	1.5	141
9	Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology, 2009, 73, 1469-1477.	1.5	136
10	Road safety in drivers with Parkinson disease. Neurology, 2009, 73, 2112-2119.	1.5	136
11	Body mass index in Parkinson's disease: A meta-analysis. Parkinsonism and Related Disorders, 2012, 18, 263-267.	1.1	129
12	Impaired navigation in drivers with Parkinson's disease. Brain, 2007, 130, 2433-2440.	3.7	128
13	Neuropsychological Predictors of Driving Errors in Older Adults. Journal of the American Geriatrics Society, 2010, 58, 1090-1096.	1.3	121
14	Driving with distraction in Parkinson disease. Neurology, 2006, 67, 1774-1780.	1.5	118
15	Predictors of weight loss in Parkinson's disease. Movement Disorders, 2006, 21, 930-936.	2.2	116
16	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. Npj Parkinson's Disease, 2018, 4, 19.	2.5	110
17	Driver landmark and traffic sign identification in early Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 764-768.	0.9	109
18	Driving under low-contrast visibility conditions in Parkinson disease. Neurology, 2009, 73, 1103-1110.	1.5	97

#	Article	IF	CITATIONS
19	Parkinson disease and driving. Neurology, 2012, 79, 2067-2074.	1.5	94
20	Randomized trial of cognitive speed of processing training in Parkinson disease. Neurology, 2013, 81, 1284-1290.	1.5	89
21	Predictors of driving outcomes in advancing age Psychology and Aging, 2012, 27, 550-559.	1.4	86
22	Cognitive functioning differentially predicts different dimensions of older drivers' on-road safety. Accident Analysis and Prevention, 2015, 75, 236-244.	3.0	76
23	Driving and neurodegenerative diseases. Current Neurology and Neuroscience Reports, 2008, 8, 377-383.	2.0	74
24	Unsafe rear-end collision avoidance in Alzheimer's disease. Journal of the Neurological Sciences, 2006, 251, 35-43.	0.3	72
25	Cognitive impairment and dementia in Parkinson's disease: Practical issues and management. Movement Disorders, 2014, 29, 663-672.	2.2	69
26	Prediction of driving ability with neuropsychological tests: Demographic adjustments diminish accuracy. Journal of the International Neuropsychological Society, 2010, 16, 679-686.	1.2	66
27	Real-life driving outcomes in Parkinson disease. Neurology, 2011, 76, 1894-1902.	1.5	66
28	Neuropsychological assessment of driving safety risk in older adults with and without neurologic disease. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 895-905.	0.8	57
29	The midlatency auditory evoked potential P50 is abnormal in Huntington's disease. Journal of the Neurological Sciences, 2003, 212, 1-5.	0.3	53
30	Deep Brain Stimulation in Movement Disorders. Seminars in Neurology, 2007, 27, 170-182.	0.5	50
31	Expression of mRNAs of multiple growth factors and receptors by astrocytes and glioma cells: Detection with reverse transcription-polymerase chain reaction. Cellular and Molecular Neurobiology, 1995, 15, 221-237.	1.7	49
32	Driving and offâ€road impairments underlying failure on road testing in Parkinson's disease. Movement Disorders, 2013, 28, 1949-1956.	2.2	44
33	Cognitive Functioning Predicts Driver Safety on Road Tests 1 and 2ÂYears Later. Journal of the American Geriatrics Society, 2012, 60, 99-105.	1.3	34
34	Naturalistic Distraction and Driving Safety in Older Drivers. Human Factors, 2013, 55, 841-853.	2.1	32
35	Impact of specific executive functions on driving performance in people with Parkinson's disease. Movement Disorders, 2013, 28, 1941-1948.	2.2	32
36	Establishing an evidence-base framework for driving rehabilitation in Parkinson's disease: A systematic review of on-road driving studies. NeuroRehabilitation, 2015, 37, 35-52.	0.5	32

#	Article	IF	CITATIONS
37	Cerebellar Transcranial Direct Current Stimulation in People with Parkinson's Disease: A Pilot Study. Brain Sciences, 2020, 10, 96.	1.1	32
38	Microvascular decompression and MRI findings in trigeminal neuralgia and hemifacial spasm. A single center experience. Clinical Neurology and Neurosurgery, 2015, 139, 216-220.	0.6	31
39	Niemann-Pick disease type C: Two cases and an update. Movement Disorders, 2000, 15, 1199-1203.	2.2	29
40	Approach to Cognitive Impairment in Parkinson's Disease. Neurotherapeutics, 2020, 17, 1495-1510.	2.1	29
41	Albuterol Improves Response to Levodopa and Increases Skeletal Muscle Mass in Patients With Fluctuating Parkinson Disease. Clinical Neuropharmacology, 2003, 26, 207-212.	0.2	28
42	Detection of imminent collisions by drivers with Alzheimer's disease and Parkinson's disease: A preliminary study. Accident Analysis and Prevention, 2010, 42, 852-858.	3.0	27
43	Driving difficulties in Parkinson's disease. Movement Disorders, 2010, 25, S136-40.	2.2	26
44	Validation of a screening battery to predict driving fitness in people with Parkinson's disease. Movement Disorders, 2013, 28, 671-674.	2.2	25
45	Longitudinal decline of driving safety in Parkinson disease. Neurology, 2017, 89, 1951-1958.	1.5	24
46	Cognitive Abilities Related to Driving Performance in a Simulator and Crashing on the Road. , 2005, , .		24
47	Driving impairment and crash risk in Parkinson disease. Neurology, 2018, 91, e906-e916.	1.5	23
48	Clinical predictors of driving status in Huntington's disease. Movement Disorders, 2012, 27, 1146-1152.	2.2	22
49	Childhood dystonia. Seminars in Pediatric Neurology, 2003, 10, 52-61.	1.0	19
50	Gestures make memories, but what kind? Patients with impaired procedural memory display disruptions in gesture production and comprehension. Frontiers in Human Neuroscience, 2014, 8, 1054.	1.0	18
51	On-road driving impairments in Huntington disease. Neurology, 2014, 82, 956-962.	1.5	17
52	A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 94, 79-83.	1.1	17
53	Ascertainment of On-Road Safety Errors Based on Video Review. , 2009, 2009, 419-426.		14
54	Driving in Parkinson Disease. Clinics in Geriatric Medicine, 2020, 36, 141-148.	1.0	11

#	Article	IF	CITATIONS
55	Juvenile parkinsonism. Seminars in Pediatric Neurology, 2003, 10, 62-67.	1.0	10
56	The sleep state-dependent midlatency auditory evoked P50 potential in various disorders. Thalamus & Related Systems, 2002, 2, 9-19.	0.5	9
57	β-Adrenergics enhance brain extraction of levodopa. Movement Disorders, 2002, 17, 54-59.	2.2	8
58	Separating the effect of reward from corrective feedback during learning in patients with Parkinson's disease. Cognitive, Affective and Behavioral Neuroscience, 2017, 17, 678-695.	1.0	8
59	Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. International Journal of Neuroscience, 2017, 127, 841-848.	0.8	8
60	Route-Following and Safety Errors by Drivers with Stroke. Transportation Research Record, 2004, 1899, 90-95.	1.0	4
61	Driver Identification of Landmarks and Traffic Signs after a Stroke. , 0, .		4
62	Non-motor Symptoms in Parkinson's Disease. European Neurological Review, 2012, 7, 35.	0.5	3
63	Driver Identification of Landmarks and Traffic Signs after a Stroke. Transportation Research Record, 2005, 1922, 9-14.	1.0	2
64	β-Adrenergics enhance brain extraction of levodopa. , 2002, 17, 54.		2
65	COLLISION AVOIDANCE TRAINING USING A DRIVING SIMULATOR IN DRIVERS WITH PARKINSON'S DISEASE: A PILOT STUDY. , 2009, 2009, 154-160.		2
66	Parkinson hastalığında sürücülük. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2014, 20, 6	4 <i>3</i> .1.	1
67	Impaired Curve Negotiation in Drivers with Parkinson's Disease. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2009, 15, 10-18.	0.1	1
68	DRIVER REHABILITATION IN PARKINSON'S DISEASE USING A DRIVING SIMULATOR: A PILOT STUDY. , 2011, 2011, 248-254.		1
69	Real-life consequences of cognitive dysfunction in Parkinson's disease. Progress in Brain Research, 2022, 269, 113-136.	0.9	1
70	Chapter 9 Clinical Trials in Parkinson's Disease. Blue Books of Practical Neurology, 2001, , 173-199.	0.1	0
71	Driving Risk in Patients with Movement Disorders. , 2013, , 355-373.		0
72	Driving in Parkinson's Disease. Current Clinical Neurology, 2019, , 129-133.	0.1	0

Ergun	
LKOUN	uc

#	Article	IF	CITATIONS
73	Driving in Parkinson's Disease. Current Clinical Neurology, 2022, , 555-576.	0.1	Ο
74	beta2-Adrenergic Agonists in the Treatment of Muscle Atrophy. , 2005, , 311-324.		0
75	Relative rates of visual and cognitive decline in Alzheimer's Disease. Journal of Vision, 2010, 6, 967-967.	0.1	Ο
76	Driving Simulator Performance in Charcot-Marie-Tooth Disease Type 1A. SAE International Journal of Transportation Safety, 0, 7, .	0.4	0